Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Effect of 'Mindfulness of Breathing' on Chronic Migraine

13 novembre 2026 mis à jour par: Dr Ashish Kumar Duggal, Dr. Ram Manohar Lohia Hospital

Migraine is a common disabling primary headache disorder ranked as the third most prevalent disorder in the world. Chronic migraine (CM) is described as a headache occurring on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of a migraine headache. Chronic migraine typically evolves from episodic migraine with an annual progression rate of ~3%. CM is an important treatable cause of neurological disability . It impacts, on an average, 1.4-2.2% of the global population and imposes a significant individual and socioeconomic burden with disability scores reported to be nearly twice as high.

It is vital to make a diagnosis and ensure that any concomitant medical or psychological conditions are treated in parallel with interventions aimed at reducing the biological tendency to headaches. The conventional treatment for migraine therapy is medical therapy. However only half of the patients respond to medications and preventive drug treatments; and about 10% discontinue medications due to adverse events. Moreover almost half of the patients are not satisfied with the present treatment. There is a clear need for additional preventive strategies in the current treatment regimens for migraines due to existing shortcomings of medical management of CM. In addition, there are other tactics that can be used, such as practicing alternative medicine through Yoga and Meditation.

Meditation has been found to help in reducing stress and changing the psychological state of a person. Mindfulness meditation has been derived from Vipassana, an age old meditation technique and has been practiced since long. Buddhist literature has detailed description about the techniques of Vipassana. Mindfulness of Breathing called as 'Anapanasati Meditation', in Buddhist scriptures is the first step in the practice of Vipassana meditation. It is a technique that involves observing natural and normal breathing. As it enters and exits the body our breath acts as a connection between our conscious and unconscious minds and the voluntary and involuntary processes of our body. By observing our breath, we can gain insight into the nature of our mind and its tendency to be inconsistent and fleeting.Slowly, this technique helps develop concentration of the mind and become calm. . It is a simple and scientific method that can be easily learned. Using Mindfulness of Breathing (Anapanasati) as a tool to reduce stress can be helpful in reducing the disability associated with migraines, as stress is a common trigger for migraines.

In the present study we aim to evaluate the beneficial effects of this simple meditation technique in management of CM.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:-1. All patients between 18-60 years of age fulfilling the criteria for chronic migraine as defined by ICHD -3.3 2. Patients willing to carry out meditation as prescribed. 3. Patients on a maximum of one concomitant preventive medication for not less than 3 months duration and a stable dose for at least 1 month prior to randomization.

Exclusion Criteria:-1. 1.Patients < 18 years and > 60 years of age. 2. Prior Neurologic diseases like brain tumors, dementia, seizures, encephalitis, meningitis, and stroke. 3. Patients overusing barbiturate-containing analgesics, opioids, or subjects with medical conditions attributable to medication overuse (e.g. peptic ulcer disease from overuse of nonsteroidal anti-inflammatory drugs [NSAIDS]).

4. Patients who did not complete the headache diary for more than 6 non-consecutive days during the baseline period.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Supervised Meditation Group

The 'Meditation' group will take part in structured 'Mindfulness of Breathing' meditation sessions. A total of five sessions will be conducted on days 0, 7, 14, 28 and week 8th at the Yoga Department of ABVIMS and Dr RML Hospital. These sessions will be supervised by a yoga instructor who will explain the procedure and answer any queries. The patients will then practice the meditation alongside the instructor, as described in the subsequent sections. They will also be encouraged to continue this practice daily at home, using a 20-minute audio guide featuring the voice of the 'Late Shri S.N. Goenka Ji'. Additionally, the 'Meditation group' will join a WhatsApp group for enhanced supervision by the Yoga instructor, in which members will be required to provide daily updates after their meditation sessions. If they fail to report their daily meditation, the admin would remind them to ensure that they complete it, and their queries and issues will also addressed.

The technique taught by the late Shri S.N. Goenka Ji involved sitting with closed eyes in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily.The practitioner will have to observe the breath as instructed, without judging its length or type. The nature of the breath will have to be accepted as it is and should not be altered. Any thoughts that arise are to be acknowledged without judgment. If the mind wanders, one has to notice this and gently shift awareness back to the breath without clinging to it or wishing it to be different. If any pain, discomfort, or other sensations are felt, these are to be acknowledged with awareness before returning attention to the breath. The subject simply follows the instructions of a pre-recorded 'Mindfulness of Breathing Meditation (Anapana)' audio provided by the yoga instructor throughout the sessions.

Comparateur factice: Unsupervised Meditation Group

The Unsupervised meditation/Sham group will practice meditation on their visits-on days 0, 7, 14, 28, and week 8-without any supervision. The Yoga instructor will merely guide them once to independently concentrate on their breathing. They will not be provided any audio. This will serve as a sham group for more effective comparison and ensured blinding.

Patients were told to meditate on their own .They were not provided with any structured meditation technique. They were told to meditate in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily on their own without any specific instructions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To assess the change in headache days at 12 weeks from baseline.
Délai: From enrollment to 12 Weeks.

Change in frequency of moderate-severe headache days per month from baseline (Headache-day is defined as a calendar day [00:00 to 23:59] when the patient reported > 4 continuous hours of headache in the diary) during the month 2-3.

From enrollment to 12 Weeks.

Mesures de résultats secondaires

Mesure des résultats
Délai
Change in migraine days (week 8 - 12 vs baseline)
Délai: 12 weeks
12 weeks
50% responder rate
Délai: 12 weeks
12 weeks

Autres mesures de résultats

Mesure des résultats
Délai
Change in headache severity (week 8 - 12 vs baseline)
Délai: 12 weeks
12 weeks
Change in number of days with acute medication use (week 8 - 12 vs baseline)
Délai: 12 weeks
12 weeks
Change in PHQ-9 scores (week 8 - 12 vs baseline)
Délai: 12 weeks
12 weeks
Change in MIDAS score ( week 8-12 vs baseline)
Délai: 12 weeks
12 weeks
Change in HIT (week 8-12 vs baseline)
Délai: 12 weeks
12 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

15 août 2027

Achèvement de l'étude (Estimé)

15 août 2027

Dates d'inscription aux études

Première soumission

13 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IEC/ABVIMS/RMLH/1410

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

IPD related to the study will be shared by the principal investigator on request.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner